Catheter Precision Receives First Purchase Order for LockeT in Germany
Rhea-AI Summary
Catheter Precision (NYSE/American: VTAK) announced receipt of its first LockeT purchase order in Germany from Universitätsklinikum Frankfurt on January 22, 2026. The order marks LockeT's official entry into the German market and installs the company's suture retention device designed to improve workflow after venous catheter access while remaining cost effective. Catheter Precision cited Germany as the largest healthcare market in Europe and referenced a $900 million German electrophysiology devices market size for 2024. The Frankfurt university hospital will act as a reference site as the company scales operations across Germany and broader Europe.
Positive
- First LockeT purchase order received in Germany (Universitätsklinikum Frankfurt)
- Official market entry into Germany, Europe’s largest hospital sector
- Reference site at Frankfurt university hospital to support European expansion
Negative
- None.
News Market Reaction
On the day this news was published, VTAK gained 10.45%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $375K to the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre‑news, VTAK was down 3.83% while peers were mixed: NUWE up 0.54%, BBLG, BJDX, NAOV and VERO down, with VERO off 7.8%. Momentum scanner only flagged VERO moving down, suggesting stock‑specific rather than sector‑wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | VIVO order Slovenia | Positive | -1.9% | New VIVO purchase order expands footprint to 15 countries. |
| Dec 18 | LockeT Ireland deal | Positive | +0.9% | First LockeT order and multi‑year commitment at major Irish EP center. |
| Dec 03 | VIVO Hungary tender | Positive | +13.3% | Multi‑year tender win for VIVO at leading Hungarian university hospital. |
| Dec 01 | LockeT Switzerland launch | Positive | -3.3% | Commercial launch of LockeT in Switzerland with first clinical cases. |
| Nov 25 | ASC reimbursement change | Positive | +12.1% | New U.S. ASC reimbursement for EP ablations highlighted as LockeT opportunity. |
Positive commercialization and market‑access headlines have produced mixed reactions, with both strong gains and sell‑offs on expansion news.
Over the last few months, Catheter Precision has focused on European expansion and market access. VIVO and LockeT won tenders and purchase orders in Slovenia, Hungary and Ireland, and LockeT launched commercially in Switzerland, with over 10,000 units shipped globally. A U.S. reimbursement change effective January 1, 2026 was framed as a major LockeT opportunity. Today’s German LockeT order continues this strategy of leveraging reference centers and distribution to grow adoption.
Market Pulse Summary
The stock surged +10.4% in the session following this news. A strong positive reaction aligns with the strategic significance of securing a first LockeT purchase order in Germany, described as the largest European healthcare and a >$900 million electrophysiology devices market. Past European expansion headlines for VIVO and LockeT have sometimes led to sizeable gains but also mixed follow‑through, so investors have historically weighed commercialization wins against the company’s broader financial and execution risks.
Key Terms
cardiac electrophysiology medical
suture retention device technical
venous catheter access medical
AI-generated analysis. Not financial advice.
FORT MILL, S.C., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a LockeT purchase order from Universitätsklinikum Frankfurt (Frankfurt University Hospital). This purchase order marks the official entry of LockeT into Germany.
The purchase order includes the LockeT suture retention device, a state-of-the-art solution designed to increase workflow efficiency after venous catheter access while remaining cost effective. By partnering with one of Germany’s premier university hospitals, Catheter Precision establishes a significant foothold in a market renowned for its innovation and high standards for medical excellence.
"Securing our first purchase order from a prestigious German university hospital is a definitive turning point for Catheter Precision,” said David Jenkins, CEO of Catheter Precision. "Germany represents the most significant healthcare market in Europe, with the German Electrophysiology Devices Market size valued at over
Germany’s hospital sector is the largest in Europe, with university hospitals serving as the primary drivers of innovation and high-tech medical adoption. This first implementation at Universitätsklinikum Frankfurt will serve as a reference site for Catheter Precision as it continues to scale operations across Germany and the broader European market.
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What did Catheter Precision announce about LockeT in Germany on January 22, 2026?
Which hospital placed the first LockeT order for VTAK and why is it significant?
How did Catheter Precision describe the German electrophysiology market in the January 22, 2026 release?
What is the LockeT device purpose mentioned in the VTAK announcement?
Will the Universitätsklinikum Frankfurt implementation affect Catheter Precision’s European plans?
